GlassScriptPhysician profile
Katlin C Davis
NPI 1114576196
$1,085.00
in general payments reported to CMS, 2019-2025
16 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $323 · 2022: $231 · 2023: $278 · 2024: $132 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $531.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $227.67 | 2022-2023 | Lokelma, Farxiga |
| Fresenius USA Marketing, INC. | $190.41 | 2021-2025 | Velphoro, Velphoro, Korsuva |
| Alexion Pharmaceuticals, INC. | $169.05 | 2021-2023 | Ultomiris |
| Silk Road Medical, INC. | $120.28 | 2021 | |
| Vifor Pharma, INC. | $62.75 | 2022-2024 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $53.55 | 2021-2023 | |
| Baxter Healthcare | $50.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $32.64 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.31 | 2025 | Caplyta |
| Calliditas Therapeutics US INC. | $30.04 | 2022-2024 | |
| Opko Pharmaceuticals, LLC | $29.08 | 2022-2023 | Rayaldee |
| Amgen INC. | $27.28 | 2024 | Krystexxa |
| Radiometer America, INC | $18.42 | 2025 | |
| Glaxosmithkline, LLC. | $16.51 | 2022 | |
| Novo Nordisk INC | $14.82 | 2023 | Ozempic, Rybelsus |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katlin Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.